camel-derived anti-influenza virus antibodies (Canopus)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namecamel-derived anti-influenza virus antibodies (Canopus)
Drug Alias NameCamel-derived anti-H5N1 influenza virus antibodies (Canopus)camel-derived anti-H5N2 influenza virus antibodies (Canopus)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsInfluenza, Human
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndiaMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesCanopus BioPharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCanopus BioPharma Inc
Active IndicationsN/A
Inactive IndicationsInfluenza, Human

Other Information

ATC CodeN/A
Related LinksN/A